Among them, tazemetostat developed by Epizyme and Eisai is an oral competitive inhibitor of the SAM pocket of the EZH2 SET domain, and received accelerated approval in January 2020 in the USA for the treatment of adults and adolescents aged ≥16 years with locally advanced or metastatic epithelioid sarcoma not eligible for complete resection (Table 4). This evidence concerns the gene EZH2 and epithelioid sarcoma.